High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter...

Area of Science:

• Nephrology
• Critical Care Medicine
• Pharmacology

Background:

• The efficacy of furosemide in acute renal failure (ARF) patients remains a subject of debate.
• Understanding furosemide's impact on survival and renal recovery in ARF is crucial for clinical practice.

Purpose of the Study:

• To evaluate the effect of high-dose furosemide on survival and renal recovery in patients with acute renal failure.
• To assess the impact of furosemide on dialysis requirements and urinary output in ARF patients.

Main Methods:

• A randomized controlled trial involving 338 patients with ARF requiring dialysis.
• Patients received either high-dose furosemide (intravenous or oral) or a matched placebo.
• Primary endpoint was survival; secondary endpoints included dialysis sessions, time on dialysis, and time to achieve specific creatinine and diuresis levels.

Main Results:

• No significant differences were observed in survival or renal recovery rates between furosemide and placebo groups.
• Furosemide significantly reduced the time to achieve a 2-L/d diuresis compared to placebo (5.7 vs. 7.8 days).
• While more patients on furosemide achieved a 2-L/d diuresis (57% vs. 33%), there were no differences in dialysis sessions or duration.

Conclusions:

• High-dose furosemide administration in patients with established ARF enhances urinary output.
• Furosemide does not demonstrate a significant impact on the survival rates of ARF patients.
• Renal recovery rates were not improved by furosemide treatment in this ARF patient cohort.